Enterprise Value

-9.057M

Cash

34.22M

Avg Qtr Burn

-4.135M

Short % of Float

1.40%

Insider Ownership

0.46%

Institutional Own.

7.41%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rigosertib Details
Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer

Phase 2

Data readout

Narazaciclib w/ letrozole Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Rigosertib (RAS inhibitor) + Nivolumab + pembrolizumab Details
Non-small cell lung carcinoma, Cancer, Cutaneous squamous cell carcinoma

Phase 1/2

Data readout

Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details
Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer

Phase 1

Update

Rigosertib Details
Myelodysplastic syndrome

Failed

Discontinued